A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
about
Antitumor and Antimetastatic Effect of Small Immunostimulatory RNA against B16 Melanoma in MiceA nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanomaEfficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.Methylation-mediated molecular dysregulation in clinical oral malignancyGSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase SignalingsImpact of temozolomide on immune response during malignant glioma chemotherapyUrsolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expressionConditionally replicating adenoviruses carrying mda-7/IL-24 for cancer therapy.Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.Adenovirus-based strategies enhance antitumor capability through p53-mediated downregulation of MGMT in uveal melanoma.Temozolomide-perillyl alcohol conjugate downregulates O6-methylguanin DNA methltransferase via inducing ubiquitination-dependent proteolysis in non-small cell lung cancer.Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
P2860
Q27318732-37832FC9-EFBC-4064-8CC5-1424DC9422BAQ30412393-837C09A4-8EA6-47AC-A529-31617F2FC5F1Q34497045-99A70A52-7277-4C9E-A7D8-A3089C5CB7DEQ35026931-E13E362D-302D-4047-A916-69D803606D7EQ35974424-895B58DE-465C-49AB-A38C-C84F184E7FA2Q36105554-6AF3F576-9D91-4D02-A62D-D99DD08353C6Q36362798-1C2D8CB5-089C-4B00-BD73-F6FE34756A47Q37144157-5AACD1AF-1DAA-4EA6-A641-F963718B9716Q37945288-2CCB3014-7BE8-4A6B-AF8C-21BB71BE9ADCQ38225830-244A55B3-5869-443E-B490-C313FD8CDE10Q38788915-1E64CCEB-946D-4C7F-926B-7E612D0AE0C3Q38830917-1AD30C37-AD51-4413-98AA-D911EC609426Q41696382-8F8C97A7-739A-4739-AB66-5F770676A674Q41985299-EAAF1C54-6578-4645-8595-F17A4BED88D1Q50091180-DD0CB840-7B97-4399-B828-F15BED2D9FE4Q51735700-EBB3B841-F32A-4B8E-9C32-CC4F1BD5B665
P2860
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel approach to overcome t ...... ation of MGMT by gene therapy.
@en
A novel approach to overcome t ...... ation of MGMT by gene therapy.
@nl
type
label
A novel approach to overcome t ...... ation of MGMT by gene therapy.
@en
A novel approach to overcome t ...... ation of MGMT by gene therapy.
@nl
prefLabel
A novel approach to overcome t ...... ation of MGMT by gene therapy.
@en
A novel approach to overcome t ...... ation of MGMT by gene therapy.
@nl
P2093
P1476
A novel approach to overcome t ...... ation of MGMT by gene therapy.
@en
P2093
Dong-Sheng Pei
Guan Jiang
Jun-Nian Zheng
Yan-Qun Liu
Zhi-Ping Wei
P304
P356
10.1016/J.BBRC.2011.02.042
P407
P577
2011-02-15T00:00:00Z